Understanding the Afrezza Inhaler: A Rapid-Acting Inhaled Insulin System

The Afrezza inhaler represents a significant advancement in insulin delivery technology, offering a needle-free alternative for adults with type 1 and type 2 diabetes. This dry-powder formulation of human insulin is inhaled through a small, breath-powered device, delivering insulin directly to the deep lung tissue where it is rapidly absorbed into the bloodstream. The pharmacokinetic profile of Afrezza closely mimics the natural first-phase insulin response that occurs after a meal, making it particularly effective for managing postprandial glucose spikes.

Unlike traditional injectable rapid-acting insulin analogs such as lispro or aspart, Afrezza reaches peak concentration in the blood approximately 12–15 minutes after inhalation and returns to near-baseline levels within 90–180 minutes. This rapid onset and short duration of action allow patients to take Afrezza at the start of a meal—or within 20 minutes of beginning to eat—without the need to wait for an insulin bolus to take effect. For many users, this flexibility can simplify mealtime insulin management and reduce the burden of multiple daily injections.

Components of the Afrezza Inhaler System

The Afrezza system consists of three main components:

  • The reusable inhaler device: A small, plastic, breath-powered device about the size of a whistle. It contains a mechanism to puncture the insulin cartridge and allow airflow through the powdered insulin.
  • Single-use insulin cartridges: Each cartridge contains a precise dose of dry-powder human insulin. Cartridges are available in three strengths: 4 units (blue), 8 units (green), and 12 units (yellow). The color-coding system helps patients quickly identify the correct dose.
  • Disposable mouthpieces: Each cartridge is housed within a disposable mouthpiece unit that is used for a single inhalation. The mouthpiece is discarded after each use, and a new one is attached to the inhaler for the next dose.

The entire system is designed to be intuitive and portable. The inhaler device itself can be reused for up to 15 days (based on typical use of three cartridges per day) before needing replacement. Each cartridge is individually wrapped in foil to protect the powder from moisture and light.

Preparing the Afrezza Inhaler for Use

Before each dose, patients must complete a simple preparation sequence to ensure the device functions correctly and the insulin is delivered effectively.

Inspecting the Device and Cartridge

  • Check the expiration date on the cartridge foil wrapper. Do not use if the cartridge is expired.
  • Inspect the inhaler device for cracks, dirt, or damage. If the device appears compromised, discard it and use a new one.
  • Ensure the mouthpiece cover is clean and free of debris. Wash the cover with mild soap and water if needed, and dry thoroughly before use.

Loading the Cartridge

To load a new cartridge:

  1. Open the inhaler by pulling the blue mouthpiece cover upward until the device clicks open.
  2. Remove a single cartridge from its foil wrapper. Hold the cartridge at the base (the wider end) to avoid touching the mouthpiece.
  3. Insert the cartridge into the square opening in the inhaler, aligning the notches. Push down firmly until the cartridge clicks into place. The cartridge and mouthpiece are now attached as a single unit.
  4. Close the mouthpiece cover by pressing it down until it clicks shut. The device is now ready for inhalation.

It is critical not to load a cartridge until just before use. Once the foil wrapper is opened, the cartridge should be used within 10 minutes. Prolonged exposure to air can degrade the insulin powder.

Step-by-Step Inhalation Technique

Proper inhalation technique is essential for delivering the full dose of insulin to the lungs. The device is breath-activated, meaning the patient’s own inspiratory effort draws the powder out of the cartridge.

Correct Breathing Sequence

  1. Exhale fully: Before placing the inhaler in your mouth, breathe out completely to empty your lungs. Do not exhale into the inhaler, as moisture from your breath can clog the device.
  2. Seal your lips around the mouthpiece: Hold the inhaler horizontally, with the blue mouthpiece cover facing you. Place your lips tightly around the mouthpiece, creating an airtight seal.
  3. Inhale deeply and forcefully: Take a single, deep, rapid breath through the inhaler. You should hear a slight rattling sound as the insulin powder moves through the device. This indicates the dose is being released.
  4. Hold your breath: Remove the inhaler from your mouth and hold your breath for about 5 seconds (or as long as comfortably possible) to allow the insulin to settle in the lungs and be absorbed.
  5. Exhale slowly: Breathe out normally, away from the inhaler.

After each inhalation, remove the used cartridge and mouthpiece by opening the device and pressing the release button (if equipped) or simply pulling the cartridge upward. Dispose of the cartridge and mouthpiece in regular household trash. Do not reuse cartridges or mouthpieces. Wash or wipe the inhaler device as directed in the user manual.

Common Mistakes to Avoid

  • Do not shake the inhaler before or after loading the cartridge. Shaking can dislodge the powder or damage the mechanism.
  • Do not blow into the inhaler at any point. Exhaling into the device can introduce moisture and cause the powder to clump, reducing the delivered dose.
  • Do not take more than one inhalation per cartridge. Each cartridge contains the entire dose; a second inhalation will not deliver additional insulin.
  • Do not use the inhaler if you are sick with a respiratory infection, have active bronchitis, or are experiencing significant wheezing or coughing.

Understanding Afrezza Dosage

Afrezza dosing differs from injectable insulin because the bioavailability of inhaled insulin is variable and depends on lung function, inhalation technique, and individual metabolic factors. The device delivers insulin in unit equivalents, with 1 cartridge unit roughly equal to 1 unit of injected rapid-acting insulin, but the actual glucose-lowering effect may differ. Therefore, dose conversion from injectable insulin must be done carefully, typically with initial dose reductions of 50% when switching from injected mealtime insulin to Afrezza.

Starting Doses

The recommended starting dose for most adults is one 4-unit cartridge (blue) per meal. For patients switching from injectable rapid-acting insulin, the healthcare provider will calculate an initial dose based on the existing bolus regimen. Generally, the total daily dose of Afrezza should not exceed 48 units in patients with type 1 diabetes and 60 units in those with type 2 diabetes. However, individual needs vary.

Because Afrezza has a rapid onset and short duration, it is typically used only for meals that contain carbohydrates. For meals with minimal carbohydrates, many patients skip the dose or reduce the number of cartridges used. Patients should work with their diabetes care team to establish a pattern that matches their eating habits.

Dose Adjustments

Dose adjustments should be guided by self-monitoring of blood glucose (SMBG). The following factors may indicate a need for dose changes:

  • Blood glucose levels measured 1–2 hours after a meal are consistently above target range.
  • Frequent hypoglycemia within 2–3 hours after eating.
  • Changes in weight, activity level, or meal composition.
  • Concurrent illness or use of medications that affect glucose metabolism.

Patients should not adjust doses by more than one cartridge strength (4 units) at a time and should wait at least 2–3 days before making additional changes. Regular consultation with a healthcare provider is essential, especially during the initial titration period.

Special Populations

Afrezza has not been extensively studied in patients with chronic lung diseases such as asthma or COPD. Because lung function can affect insulin absorption, these patients should undergo spirometry before starting therapy and periodically thereafter. Afrezza is contraindicated in patients with known lung disease, such as chronic obstructive pulmonary disease (COPD) or asthma, due to an increased risk of bronchospasm and respiratory side effects.

Elderly patients and those with renal or hepatic impairment may also require lower starting doses due to decreased insulin clearance. Pregnant or breastfeeding women should only use Afrezza if clearly needed and under close supervision, as limited data exist for this population.

Safety, Side Effects, and Precautions

While Afrezza is generally well tolerated, it carries specific risks that patients must be aware of.

Common Side Effects

The most frequently reported adverse effects include:

  • Transient mild to moderate cough (occurring in up to 27% of patients in clinical trials)
  • Throat irritation or discomfort
  • Dry mouth or dysgeusia (altered taste)
  • Coughing up blood (hemoptysis) – rare but requires prompt medical evaluation

Serious Risks

  • Hypoglycemia: As with all insulins, Afrezza can cause low blood glucose. Because the onset is rapid, hypoglycemia may occur sooner after a meal compared to injectable analogs. Patients should always carry fast-acting glucose and be prepared to treat lows promptly.
  • Bronchospasm: A significant decline in lung function (FEV1) has been observed in some patients. Those with a history of asthma or COPD are at higher risk and should not use Afrezza. For other patients, routine pulmonary function testing is recommended at baseline, after 6 months, and annually thereafter.
  • Lung cancer: In clinical trials, two cases of lung cancer were reported in Afrezza-treated patients versus none in comparator groups. Although a causal link has not been established, patients with a history of lung cancer are advised against using Afrezza.

Contraindications

Afrezza must not be used in the following situations:

  • Known hypersensitivity to regular human insulin or any excipient in the formulation
  • Chronic lung disease (COPD, asthma, active bronchospasm)
  • Hypoglycemia unawareness or frequent severe hypoglycemia
  • Smoking or recent smoking cessation (within 6 months)

Comparing Afrezza to Injectable Insulin

Afrezza offers several advantages over traditional mealtime insulin injections, but it also has limitations. A 2019 meta-analysis published in Diabetes Therapy compared Afrezza to injectable rapid-acting analogs and found comparable glycemic control (HbA1c reduction) with a lower risk of weight gain and similar rates of hypoglycemia. However, patients using Afrezza experienced more coughing and had to undergo regular pulmonary function monitoring.

One of the key differences is that Afrezza cannot be used for correction doses between meals due to its short duration of action. Patients who need additional insulin coverage for snacks or high pre-meal blood glucose may need to supplement with injectable insulin or adjust their basal insulin. Afrezza is also not approved for use in intensive insulin therapy regimens that require variable doses outside of meal times.

Several patient satisfaction surveys have shown higher treatment satisfaction with Afrezza compared to injections, citing convenience, discretion, and the elimination of needle anxiety. However, the device requires a moderate level of manual dexterity and the ability to generate a forceful inhalation, which may be challenging for very elderly or impaired patients.

Storage and Maintenance

Proper storage ensures the potency of Afrezza cartridges and prolongs the life of the inhaler device.

  • Cartridges: Store unopened foil-wrapped cartridges in the refrigerator at 36°F to 46°F (2°C to 8°C). Do not freeze. Once the foil is opened, the cartridge must be used within 10 minutes. At room temperature, unused cartridges can be kept for up to 10 days, but refrigeration is preferred for long-term storage.
  • Inhaler device: Keep the device at room temperature, away from excessive heat or moisture. Clean the mouthpiece cover weekly with a dry cloth or as instructed. Do not submerge the device in water.
  • Travel: Afrezza cartridges can be transported in a cooler if refrigerated storage is unavailable during travel. The inhaler device can be carried in a dry case. Avoid leaving the device in a hot car or in direct sunlight.

Troubleshooting Common Issues

Patients may occasionally experience difficulties with the inhaler. Below are common problems and solutions:

  • No rattling sound during inhalation: This usually means the cartridge did not puncture or the powder did not release. Remove the cartridge and reload a new one. Ensure the inhaler is fully closed before inhaling.
  • Weak or no inhalation: Check that the mouthpiece is not blocked. The inhaler requires a minimum inspiratory flow rate of about 30 L/min. If you are congested or have reduced lung capacity, practice breathing exercises or consult your provider.
  • Coughing after inhalation: If the cough is mild, it may subside with continued use. If persistent, discontinue and discuss with your doctor. Drinking a glass of water before inhalation may help reduce throat irritation.
  • Device not opening or closing: Do not force the mechanism. Contact the manufacturer’s support line for a replacement device.

Clinical Efficacy and Real-World Evidence

Afrezza was approved by the U.S. Food and Drug Administration (FDA) in 2014 based on two pivotal Phase 3 trials: one in type 1 diabetes (Affinity 1) and one in type 2 diabetes (Affinity 2). Results showed non-inferiority to injectable insulin with respect to HbA1c reduction, with a smaller increase in fasting plasma glucose but a slightly higher incidence of hypoglycemia in the type 1 group. More recent real-world studies, such as a 2021 analysis of U.S. patients, have demonstrated that Afrezza can be successfully integrated into diverse insulin regimens, with a reduction in daily injection burden.

For patients who struggle with injection fatigue or needle phobia, Afrezza offers an alternative that may improve adherence to mealtime insulin therapy. However, success depends on proper training, realistic expectations about the device’s limitations, and careful dose titration.

Resources and Further Reading

For more detailed information, consult the official Afrezza website and FDA prescribing information. Clinical practice guidelines on inhaled insulin are available from the American Diabetes Association and European Association for the Study of Diabetes. Patients can also find instructional videos and support through the manufacturer’s patient portal.

Conclusion

The Afrezza inhaler provides a viable, needle-free option for mealtime insulin delivery in adults with diabetes. Its rapid absorption and short duration align well with the physiological insulin response to meals, offering convenience and flexibility. However, successful use requires mastery of inhalation technique, vigilant blood glucose monitoring, careful dose titration, and regular pulmonary function checks. Patients should work closely with their diabetes care team to determine if Afrezza fits their specific needs and to develop a personalized treatment plan. With proper adherence to usage guidelines and safety precautions, Afrezza can be a valuable tool in achieving better glycemic control and improving quality of life.